MIBio 2024

We are delighted to announce that the 12th MIBio conference will take place at the Howard Theatre, Downing College, Cambridge, on 4 December 2024.

MIBio engages leading experts from industry and academia in a discussion on how the latest molecular interaction based discoveries can be exploited in biopharmaceutical formulation to deliver more effective, patient-friendly, and safer therapeutic products.

The 2024 meeting will primarily focus on subcutaneous delivery. In spite of advances in other dosage forms and routes of administration over the last decade, subcutaneous products dominate the biopharmaceutical pipelines of Pharma and Biotech companies due to their simplicity, reliability and suitability for self-administration. The trend is further fuelled by continuous improvements of delivery devices and their digital connectivity. The state-of-the-art of the subcutaneous delivery will be discussed at MIBio 2024 as well as possible future trends. However, we will also focus on other challenges including bioavailability, and ways of addressing them.

We expect around 100 delegates from biopharma industry, academia and technology suppliers to create a stimulating event fostering new collaborations and discoveries that will help steer the development of the next generation of drug products. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots on the day.

We look forward to seeing you at MIBio 2024!

Online Registration

Registration is now CLOSED

Programme

08:00 Registration opens

09:00 Opening remarks

09:15 Subcutaneous Delivery of Biologics: Challenges and Solutions
Prof. Samir Mitragotri | Harvard University, USA

09:45 End-to-end considerations for the development of High-Conc biologic drug product from early development to launch
Kishore Ravuri | Roche, Switzerland

10:15 Speed Networking

11:15 Pioneering mAb Subcutaneous Bioavailability Prediction: A Novel Validated Approach
Isabelle Trayton and Belal Hanafy| AstraZeneca, UK

11:45 Predicting clinical bioavailability and efficacy with preclinical interstitial sampling
Thomas Birngruber | Joanneum Research, Austria

12:15 Lunch Break, Exhibition and Posters

13:30 Introduction to the afternoon session

13:45 Discussion panel

14:45 Exhibitors highlights

15:30 Coffee break, Exhibition and Posters

16:00 Harnessing the potential of metallic nanohybrids in cancer theranostics
Clare Hoskins | University of Strathclyde, UK

16:30 Evolution of formulation space for mAbs from IV to SC
Sumantha Dayananda | Ten23 Health, Switzerland

17:00 Concluding remarks

17:10 Conference ends

Exhibitors & Sponsors

Our Joint Exhibitors & Sponsors

Exhibitors & Sponsors

Our Exhibitors